BRPI0811732A2 - Formulação de liberação prolongada de nevirapina - Google Patents

Formulação de liberação prolongada de nevirapina

Info

Publication number: BRPI0811732A2
Authority: BR; Brazil
Prior art keywords: nevirapine; release formulation; prolonged release; prolonged; formulation
Prior art date: 2007-06-08

Application number

BRPI0811732-2A2A

Other languages

English (en)

Inventor

Michael L Cappola

Svetlana Sienkiewicz

Glenn Charles Snow

Feng-Jing Chen

Original Assignee

Boehring Ingelheim Internat Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-08

Filing date

2008-06-04

Publication date

2014-11-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39739795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0811732(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-06-04 Application filed by Boehring Ingelheim Internat Gmbh filed Critical Boehring Ingelheim Internat Gmbh

2014-11-18 Publication of BRPI0811732A2 publication Critical patent/BRPI0811732A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI0811732-2A2A 2007-06-08 2008-06-04 Formulação de liberação prolongada de nevirapina BRPI0811732A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US94276507P	2007-06-08	2007-06-08
PCT/US2008/065705 WO2008154234A2 (en)	2007-06-08	2008-06-04	Extended release formulation of nevirapine

Publications (1)

Publication Number	Publication Date
BRPI0811732A2 true BRPI0811732A2 (pt)	2014-11-18

Family

ID=39739795

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0811732-2A2A BRPI0811732A2 (pt)	2007-06-08	2008-06-04	Formulação de liberação prolongada de nevirapina

Country Status (28)

Country	Link
US (1)	US8460704B2 (pt)
EP (1)	EP2155169B1 (pt)
JP (1)	JP5417662B2 (pt)
KR (1)	KR101017862B1 (pt)
CN (1)	CN101784263B (pt)
AR (1)	AR066924A1 (pt)
AU (1)	AU2008262031B2 (pt)
BR (1)	BRPI0811732A2 (pt)
CA (1)	CA2687491C (pt)
CL (1)	CL2008001678A1 (pt)
CO (1)	CO6150128A2 (pt)
DK (1)	DK2155169T3 (pt)
EA (1)	EA018377B1 (pt)
EC (1)	ECSP099561A (pt)
ES (1)	ES2574836T3 (pt)
HU (1)	HUE028598T2 (pt)
IL (1)	IL199924A0 (pt)
MA (1)	MA31430B1 (pt)
MX (1)	MX2009007764A (pt)
NZ (1)	NZ578664A (pt)
PE (2)	PE20131035A1 (pt)
PL (1)	PL2155169T3 (pt)
TN (1)	TN2009000510A1 (pt)
TW (1)	TWI419716B (pt)
UA (1)	UA97971C2 (pt)
UY (1)	UY31128A1 (pt)
WO (1)	WO2008154234A2 (pt)
ZA (1)	ZA200904939B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY149159A (en)	2005-11-15	2013-07-31	Hoffmann La Roche	Method for treating joint damage
US20130172274A1 (en)	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
DK2155169T3 (en)	2007-06-08	2016-06-13	Boehringer Ingelheim Int	Formulation of nevirapine extended release
WO2009158704A2 (en)	2008-06-27	2009-12-30	Duke University	Therapeutic agents comprising elastin-like peptides
EP2714045A1 (en)	2011-05-30	2014-04-09	Cipla Limited	Pharmaceutical antiretroviral composition
US20130084277A1 (en) *	2011-08-24	2013-04-04	Phasebio Pharmaceuticals, Inc.	Formulations of active agents for sustained release
IN2014MN01907A (pt) *	2012-03-05	2015-07-10	Cipla Ltd
CN104523630B (zh) *	2015-01-22	2017-08-25	山东新时代药业有限公司	一种奈韦拉平片剂
EP3153157A1 (en)	2015-10-09	2017-04-12	Teva Pharmaceutical Works Private Limited Company	Pharmaceutical composition for prolonged release of nevirapine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5366972A (en)	1989-04-20	1994-11-22	Boehringer Ingelheim Pharmaceuticals, Inc.	5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
US5133974A (en)	1989-05-05	1992-07-28	Kv Pharmaceutical Company	Extended release pharmaceutical formulations
CA2030056C (en)	1989-11-17	1995-10-17	Karl D. Hargrave	5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection
US5419917A (en) *	1994-02-14	1995-05-30	Andrx Pharmaceuticals, Inc.	Controlled release hydrogel formulation
US6514530B2 (en) *	1997-09-09	2003-02-04	Alza Corporation	Dosage form comprising means for changing drug delivery shape
ATE216220T1 (de)	1997-12-05	2002-05-15	Alza Corp	Osmotische darreichungsform mit zwei mantelschichten
DK1140012T3 (da) *	1998-12-17	2004-07-12	Alza Corp	Omdannelse af væskefyldte gelatinekapsler til systemer til kontrolleret frigivelsessystemer ved flere coatinger
EE05022B1 (et) *	1999-03-31	2008-06-16	Janssen Pharmaceutica N.V.	Eelthelatineeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis ja hüdrofiilne kontrollitud vabanemisega preparaat
KR100785360B1 (ko) *	1999-09-24	2007-12-18	얀센 파마슈티카 엔.브이.	항바이러스 조성물
KR100738276B1 (ko)	1999-12-09	2007-07-12	알자 코포레이션	항바이러스성 약제
US6541014B2 (en) *	2000-10-13	2003-04-01	Advancis Pharmaceutical Corp.	Antiviral product, use and formulation thereof
WO2002092095A1 (en)	2001-05-11	2002-11-21	Boehringer Ingelheim International Gmbh	Use of nevirapine to treat or prevent lipid pathology in patients with hiv that is resistant to nevirapine
US20030050620A1 (en)	2001-09-07	2003-03-13	Isa Odidi	Combinatorial type controlled release drug delivery device
AU2003287666A1 (en)	2002-11-13	2004-06-03	Control Delivery Systems, Inc.	Systemic delivery of antiviral agents
WO2004112724A2 (en)	2003-06-20	2004-12-29	Viral Genomix, Inc.	Compositions for and methods for treating hiv
DE602004005734T2 (de)	2003-10-01	2007-12-27	Lupin Ltd., Mumbai	Pharmazeutische zusammensetzung mit kontrollierter freisetzung und verfahren zu ihrer herstellung
PT1696822E (pt)	2003-11-13	2010-04-28	Psivida Inc	Implante de libertação controlada injectável com um núcleo de matriz biocorrosível e crosta biocorrosível
WO2006024668A1 (en) *	2004-09-02	2006-03-09	Janssen Pharmaceutica N.V.	Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
US20110104267A1 (en) *	2005-04-25	2011-05-05	Aurobindo Pharma Limited	Pharmaceutical compositions of antiretrovirals
WO2007000779A2 (en)	2005-06-29	2007-01-04	Panacea Biotec Ltd.	Pharmaceutical sustained release compositions and processes thereof
US9198862B2 (en)	2005-07-22	2015-12-01	Rubicon Research Private Limited	Dispersible tablet composition
FR2891459B1 (fr)	2005-09-30	2007-12-28	Flamel Technologies Sa	Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
EP1933815A2 (en) *	2005-10-14	2008-06-25	Microdose Technologies Inc.	Pharmaceutical packaging of an oral dosage combination
DK2155169T3 (en)	2007-06-08	2016-06-13	Boehringer Ingelheim Int	Formulation of nevirapine extended release

2008
- 2008-06-04 DK DK08756672.5T patent/DK2155169T3/en active
- 2008-06-04 KR KR1020097016610A patent/KR101017862B1/ko active Active
- 2008-06-04 UA UAA200908230A patent/UA97971C2/ru unknown
- 2008-06-04 EA EA200900958A patent/EA018377B1/ru not_active IP Right Cessation
- 2008-06-04 JP JP2009552940A patent/JP5417662B2/ja active Active
- 2008-06-04 PL PL08756672.5T patent/PL2155169T3/pl unknown
- 2008-06-04 US US12/523,226 patent/US8460704B2/en active Active
- 2008-06-04 MX MX2009007764A patent/MX2009007764A/es active IP Right Grant
- 2008-06-04 ES ES08756672.5T patent/ES2574836T3/es active Active
- 2008-06-04 AU AU2008262031A patent/AU2008262031B2/en not_active Ceased
- 2008-06-04 BR BRPI0811732-2A2A patent/BRPI0811732A2/pt not_active IP Right Cessation
- 2008-06-04 NZ NZ578664A patent/NZ578664A/en not_active IP Right Cessation
- 2008-06-04 WO PCT/US2008/065705 patent/WO2008154234A2/en not_active Ceased
- 2008-06-04 CA CA2687491A patent/CA2687491C/en active Active
- 2008-06-04 CN CN2008800193577A patent/CN101784263B/zh active Active
- 2008-06-04 EP EP08756672.5A patent/EP2155169B1/en not_active Revoked
- 2008-06-04 HU HUE08756672A patent/HUE028598T2/en unknown
- 2008-06-06 UY UY31128A patent/UY31128A1/es not_active Application Discontinuation
- 2008-06-06 CL CL2008001678A patent/CL2008001678A1/es unknown
- 2008-06-06 TW TW097121294A patent/TWI419716B/zh active
- 2008-06-06 AR ARP080102446A patent/AR066924A1/es unknown
- 2008-06-06 PE PE2013000070A patent/PE20131035A1/es not_active Application Discontinuation
- 2008-06-06 PE PE2008000969A patent/PE20090371A1/es not_active Application Discontinuation
2009
- 2009-07-15 ZA ZA200904939A patent/ZA200904939B/xx unknown
- 2009-07-16 IL IL199924A patent/IL199924A0/en unknown
- 2009-07-21 CO CO09075419A patent/CO6150128A2/es unknown
- 2009-08-05 EC EC2009009561A patent/ECSP099561A/es unknown
- 2009-12-04 TN TNP2009000510A patent/TN2009000510A1/fr unknown
- 2009-12-07 MA MA32400A patent/MA31430B1/fr unknown

Also Published As

Publication number	Publication date
US8460704B2 (en)	2013-06-11
JP5417662B2 (ja)	2014-02-19
TW200916127A (en)	2009-04-16
ES2574836T3 (es)	2016-06-22
AR066924A1 (es)	2009-09-23
CA2687491C (en)	2011-09-20
PL2155169T3 (pl)	2016-09-30
ECSP099561A (es)	2009-09-29
UY31128A1 (es)	2009-01-30
TN2009000510A1 (en)	2011-03-31
EA018377B1 (ru)	2013-07-30
NZ578664A (en)	2011-11-25
JP2010520891A (ja)	2010-06-17
AU2008262031B2 (en)	2011-08-25
WO2008154234A9 (en)	2009-11-26
WO2008154234A2 (en)	2008-12-18
MA31430B1 (fr)	2010-06-01
AU2008262031A1 (en)	2008-12-18
EA200900958A1 (ru)	2010-04-30
CO6150128A2 (es)	2010-04-20
CN101784263B (zh)	2012-11-07
CN101784263A (zh)	2010-07-21
HK1145806A1 (en)	2011-05-06
UA97971C2 (ru)	2012-04-10
MX2009007764A (es)	2009-09-10
TWI419716B (zh)	2013-12-21
WO2008154234A3 (en)	2010-01-21
IL199924A0 (en)	2010-04-15
EP2155169B1 (en)	2016-03-23
DK2155169T3 (en)	2016-06-13
PE20131035A1 (es)	2013-10-01
CL2008001678A1 (es)	2009-09-11
US20100278918A1 (en)	2010-11-04
EP2155169A2 (en)	2010-02-24
CA2687491A1 (en)	2008-12-18
KR20100020447A (ko)	2010-02-22
PE20090371A1 (es)	2009-04-24
KR101017862B1 (ko)	2011-03-04
ZA200904939B (en)	2010-04-28
HUE028598T2 (en)	2016-12-28

Publication	Publication Date	Title
ATE556703T1 (de)	2012-05-15	Rasagilinformulierung mit verzögerter freisetzung
BRPI0807453A2 (pt)	2014-05-20	Preparação sólida
BRPI0908785A2 (pt)	2015-07-28	Formulações herbicida
BRPI0820819A2 (pt)	2015-06-16	Formulação de anticorpos
BRPI0814188A2 (pt)	2014-10-14	Formulações
BRPI0908596A2 (pt)	2015-09-15	formulação e composição farmacêutica de liberação prolongada
BRPI0814252A2 (pt)	2015-04-14	Formulações de anticorpo
BRPI0814003A2 (pt)	2015-02-03	Formulações de anticorpo
BRPI0820381A2 (pt)	2015-05-19	Formulações farmacêuticas
BR112012011733A2 (pt)	2019-09-24	formulações de comprimido de liberação imediata
BRPI0818874A2 (pt)	2015-05-05	Liberação de agentes ativos
BRPI0811979A2 (pt)	2014-10-21	Formulação para vacinas de meningite
BRPI0922730A2 (pt)	2018-11-06	formulação de anticorpo
BRPI0920240A2 (pt)	2016-08-02	formulação de adjuvante de combinação
BRPI0818079A2 (pt)	2017-06-13	composição de lipideo
DK2125048T3 (da)	2014-10-13	Præparat
BRPI0921654A2 (pt)	2016-02-10	formulação farmacêutica
BRPI0906754A2 (pt)	2015-07-07	Formulário de dosage prolongado da libertação de paliperidone
DE602008000588D1 (de)	2010-03-18	Wälzlagervorrichtung
BRPI0912428A2 (pt)	2016-02-16	formulação farmacêutica sólida de liberação retardada
BRPI0811732A2 (pt)	2014-11-18	Formulação de liberação prolongada de nevirapina
EP2296713A4 (en)	2013-01-09	DISINFECTANT FORMULATION
BRPI0922423A2 (pt)	2015-12-15	dispositivo de liberação de fármaco
BRPI0818669A2 (pt)	2017-05-02	formulação para melhora da função gastrintestinal
EP2207567A4 (en)	2013-05-01	IMMUNOGENIC FORMULATIONS

Legal Events

Date	Code	Title	Description
2016-09-20	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 8A ANUIDADE.
2017-01-10	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.